The manufacturer of the "miracle weight-loss drug," Nuohe Nordic, has raised its full-year operating profit guidance to an increase of 40%-46%.

Wallstreetcn
2023.10.13 13:49
portai
I'm PortAI, I can summarize articles.

Novo Nordisk has raised its full-year operating profit (at constant exchange rates) guidance to a growth of 40%-46%, higher than analysts' expectations of 37.5%. The company had originally forecasted...

Novo Nordisk has raised its full-year operating profit (at constant exchange rates) guidance to a growth of 40%-46%, higher than analysts' expected growth of 37.5%. The company's original forecast was a growth of 31%-37%. Novo Nordisk's stock price in Copenhagen (NOVOB.DC) is currently down 2.35%, deviating from the historical high set on October 12. Novo Nordisk's ADR (NVO) in the US pre-market is up 1.56%. Eli Lilly's stock in the US pre-market is up nearly 1%.

Source: Wallstreetcn The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.